Takara Bio Inc.

4974

JP3460200003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-15 am EDT			5-day change	1st Jan Change
818.00 ^JPY	-0.49%		+3.02%	-22.10%

May. 13	Takara Bio Inc. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2026	CI
May. 01	Takara Bio Completes Absorption of Subsidiary ViSpot	MT

Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months

Published on 02/15/2024 at 05:26, updated on 02/15/2024 at 05:33

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Takara Bio Inc.

Takara Bio Inc. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2026	May. 13	CI
Takara Bio Completes Absorption of Subsidiary ViSpot	May. 01	MT
Takara Bio Inc. completed the acquisition of ViSpot, Inc. from Sunstar Inc.	Feb. 27	CI
Takara Bio Inc. Revises Consolidated Earnings Guidance for the Full-Year Ending March 31, 2025	Feb. 13	CI
Takara Bio Buys ViSpot For Biopharma Services	Jan. 27	MT
Takara Bio Inc. entered into an agreement to acquire ViSpot, Inc. from Sunstar Inc.	Jan. 26	CI
Takara Bio Inc. Provides Consolidated Earnings Guidance for the Second Quarter and Full-Year Ending March 31, 2025	24-08-08	CI
Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index	24-03-17	CI
Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months	24-02-15	MT
Takara Bio Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	23-11-09	CI
Jefferies Adjusts Takara Bio’s Price Target to 1,900 Yen From 2,000 Yen, Keeps at Hold	23-07-25	MT
Takara Bio Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Takara Bio Inc. Revised Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-09	CI
Takara Bio Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-11-10	CI
Takara Bio Posts Extraordinary Gains and Losses over Subsidy Grants	22-01-24	MT
Takara Bio Inc. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022	21-11-09	CI
Takara Bio : Raises Earnings Forecast for Fiscal H1	21-10-22	MT
Takara Bio Eligible to List on Tokyo Bourse's Prime Market	21-09-22	MT
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2021	21-08-06	CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year Ending March 31, 2022	21-08-06	CI
Takara Bio Inc. Reports Unaudited Consolidated Earnings Results for the Year Ended March 31, 2021	21-05-13	CI
Takara Bio Inc. Provides Earnings Guidance for the Six Months Ending September 30, 2021; Provides Earnings Guidance for the Year Ending March 31, 2022	21-05-13	CI
Takara Bio Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2020	21-02-10	CI
Takara Bio Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2021	21-02-10	CI
Nitori : Japanese stocks rise on U.S. stimulus optimism	20-10-21	RE

TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.

Employees

1,779

Sector

Biotechnology & Medical Research

Calendar

Aug. 07 - Q1 2025 Earnings Release

More about the company